Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer

[ Business Wire] – Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of IBRANCE® 125mg capsules, Pfizer’s metastatic breast cancer therapy. Read more on this. Pfizer Inc. (PFE) , with a current value of $182.06B, started trading this morning at $29.59. Looking at the stock , its one day range is $29.17 to $29.65 with a trailing 52-week range being $28.25 to $36.46. PFE shares are currently priced at 12.90x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s -4.96x earnings multiple. The company pays shareholders $1.20 per share annually in dividends, yielding 4.09%. According to a consensus of 14 analysts, the earnings estimate of $0.54 per share would be $0.03 better than the year-ago quarter and a $0.04 sequential decrease. What we find to be interesting is that the full-year EPS estimate of $2.29 is a $0.09 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $11.96 Billion. If realized, that would be a 10.13% increase over the year-ago quarter. Recently, Sun Trust Rbsn Humphrey upgraded PFE from Reduce to Neutral (Nov 25, 2015). Previously, Morgan Stanley upgraded PFE from Equal-Weight to Overweight. When considering if the stock is under or overvalued, the average price target is $39.13, which is 32.24% above where the stock opened this morning. See more in (NYSE:PFE) Similar Articles: Market Update: Pfizer Inc (NYSE:PFE) – Pfizer unit to pay $784.6 mln in Medicaid rebate settlement Market Update (NYSE:PFE): Pfizer Announces FDA Acceptance of IBRANCE® (palbociclib) Supplemental New Drug Application with Priority Review in HR+, HER2- Metastatic Breast Cancer Market Update (NYSE:PFE): Pfizer Partners with Breast Cancer Leaders to Chronicle the Lives of Women with Metastatic Breast Cancer through the Lenses of Prominent Photographers